we analyzed the three TRAR4 variants in the casecontrol sample. Allele G of SNP rs8192624 again showed association with BPAD disease status (P ¼ 0.024), while the two other SNPs showed no association ( Table 1 ). The combined analysis of both samples with rs8192624 resulted in a significant association (P ¼ 0.004) ( Table 1 ). The combined analysis of rs8192624 for the two samples resulted in a significant association (P ¼ 0.004) ( Table 1) . After application of the Bonferroni correction for multiple testing, applied since five markers had been tested, the significance persists at alpha ¼ 0.05 (P ¼ 0.02). The result remains significant even when applying a further Bonferroni correction of 2 to account for the fact that a haplotype analysis was also conducted.
rs8192624 is responsible for an amino-acid exchange (V265I) in the sixth transmembrane domain of the trace amine receptor 4 (predicted on the basis of seven transmembrane GPCR structures as depicted in the GPCR database (http://www.gpcr.org/)). However, no obvious functional sequelae are associated with this variant; valine and isoleucine are nonpolar neutral amino acids and valine in position 265 is not conserved in other species.
Our study provides evidence for the involvement of the TRAR4 locus in the etiology of BPAD. It is of interest to note that a recent study 11 has reported an association with SNPs at the 3 0 UTR of TRAR4 and schizophrenia. It could be speculated that genetic variation at this locus contributes to both disorders. However, given the differing locations of the associated SNPs within the gene, and the fact that Duan et al 11 did not observe association with rs8192624 and schizophrenia, there is currently no support for the hypothesis that a single variant contributes to both disorders. Independent replication studies in BPAD and schizophrenia using denser SNP maps are required to further define the role of TRAR4 in the etiology of psychiatric disorders. SIR-A microarray study of schizophrenia in human brains reports that, among others, two proteins affecting vitamin A (retinoid) transport and function are altered. The direction of the alteration of these proteins, aldehyde dehydrogenase 1A1 and albumin, suggest that retinoic acid (RA), the final metabolic product of the retinoid cascade, is insufficient in schizophrenia. Unavailability of RA either directly or indirectly impairs transcriptional regulation of retinoid target genes, for example, DRD2 1 and ERBB4, 2 which are candidates in schizophrenia. The identification of retinoid dysregulation as a common underlying pathway in schizophrenia suggests therapeutic interventions directed toward the development of new RA analogs. A recent series of microarray expression analyses implicate entire pathways involving oxidative stress, energy metabolism and mitochondrial function in schizophrenia prefrontal cortex. 3 Dysregulation of the synthesis of RA, which mediates oxidative stress, regulates energy expenditure and influences mitochondrial functioning and apoptosis, 4 may exert a combined, cumulative influence on these pathways. Support for this suggestion can be deduced from examination of the microarray analyses referenced above: expression of the RA-synthesizing enzyme, aldehyde dehydrogenase 1A1 (ALDH1A1), a protein that is strongly expressed in dopaminergic neurons, 5 is significantly decreased; albumin, a ubiquitous serum transporter of RA 6 and other free fatty acids, for example, docosahexaenoic acid and arachidonic acid, which ligand the retinoid X receptors 7 is highly significantly decreased. Both of these findings suggest lowered availability of retinoid receptor ligands in the schizophrenia prefrontal cortex. ALDH1A1 and albumin together with other proteins of the retinoid cascade regulate the transport to and temporal and spatial availability of RA in the brain, and thus control the transcription of retinoid targets. 8 That dysregulation of the retinoid cascade may be a contributory mechanism in schizophrenia 9 is supported by the observation that the genes coding for many of the proteins showing altered expression in this microarray study of schizophrenia prefrontal cortex are either directly or indirectly regulated by RA and retinoid receptors; for example, pyruvate kinase, muscle (PKM2), 10 mitochondrial aconitase 2 (ACO2), 11 hexokinase 1 (HK1) and malate dehydrogenase 1 (MDH1), 12 gelsolin (GSN), 13 neuron-specific enolase (ENO2), 14 cardiac muscle actin alpha (ACTC) and actinin, alpha4 (ACTN4), 15 and transferrin (TF). 16 The reliability of microarray studies reporting small differences in expression can be questionable, 17 particularly so in relation to false negatives due to the lack of resolution (hybridization without separation) and false positives due to a lack of sensitivity (multiplicity of probes; complexity of probes). However, in situ hybridization with ALD-H1A1 probes finds significant downregulation of ALDH1A1 mRNA in the ventral tegmental area in schizophrenia. 18 The hypothesis that dysregulated retinoid transport and function contributes to schizophrenia has recently received substantial additional immunohistochemical support with the discovery that expression of retinoic acid receptor alpha (RARA) protein is more than two-fold greater in the dentate gyrus in post-mortem schizophrenia brains compared to controls. 19 RAs and their analogues represent well-studied therapeutic targets in cancer and dermatology. Perusal of the literature from these fields indicates that retinoids modulate cell functioning through diverse mechanisms, including gene silencing and nuclear translocation, as well as through direct transcriptional activation. Pharmacologic successes with retinoids in cancer and dermatology and the wealth of information gleaned from these successes could inform new directions in therapies for schizophrenia, particularly in relation to mechanisms involved in neuronal programmed cell death and oxidative damage.
